Objective: to systematically evaluate the status of serum vitamin D deficiency in patients with Graves’ ophthalmopathy (GO). Methods: the case-control studies, cohort studies and randomized controlled trials associated with Graves’ ophthalmopathy were searched in PubMed, EMBASE, Cochrane Central Register of Controlled Trials (CENTRAL) and Web of Science. The literatures were screened according to inclusion, exclusion criteria and quality evaluation, and the extracted data were analyzed by Meta with ReviewManager5.4 software. Results: 5 studies were included, and the number of cases included in the study was 887. The results of Meta-analysis showed that compared with the control group, the level of vitamin D in the Graves’ ophthalmopathy group was lower than that in the control group (MD=-8.22, 95%CI: -15.75~-11.45, P < 0.001). Conclusion: the decrease of serum vitamin D level is related to the diagnosis of GO. Assessment and supplementation of vitamin D levels may be an important supplement for early treatment of GD patients. Future studies should include longitudinal studies and prospective clinical trials to further explore the mechanisms of observed associations. In view of the small number of included studies, the above conclusions need to be confirmed by more high-quality randomized studies.

Shipeng Wang, Yongwei Yu, Jinze Yang. A Meta-Analysis of Serum Vitamin D Deficiency in Graves' Ophthalmopathy. International Journal of Frontiers in Medicine (2022), Vol. 4, Issue 4: 28-33. https://doi.org/10.25236/IJFM.2022.040406.

[1] ANDERSEN S L, KNøSGAARD L. Management of thyrotoxicosis during pregnancy [J]. Best Pract Res Clin Endocrinol Metab, 2020, 34(4): 101414.

[2] BARCZYŃSKI M. Current approach to surgical management of hyperthyroidism [J]. Q J Nucl Med Mol Imaging, 2021, 65(2): 124-31.

[3] BOELAERT K, VISSER W E, TAYLOR P N, et al. ENDOCRINOLOGY IN THE TIME OF COVID-19: Management of hyperthyroidism and hypothyroidism [J]. Eur J Endocrinol, 2020, 183(1): G33-g9.

[4] KAHALY G J. Management of Graves Thyroidal and Extrathyroidal Disease: An Update [J]. J Clin Endocrinol Metab, 2020, 105(12): 3704-20.

[5] ANTONELLI A, FALLAHI P, ELIA G, et al. Graves' disease: Clinical manifestations, immune pathogenesis (cytokines and chemokines) and therapy [J]. Best Pract Res Clin Endocrinol Metab, 2020, 34(1): 101388.

[6] GONZáLEZ-GARCíA A, SALES-SANZ M. Treatment of Graves' ophthalmopathy [J]. Med Clin (Barc), 2021, 156(4): 180-6.

[7] SUBEKTI I, SOEWONDO P, SOEBARDI S, et al. Practical Guidelines Management of Graves Ophthalmopathy [J]. Acta Med Indones, 2019, 51(4): 364-71.

[8] BARTALENA L, PIANTANIDA E, GALLO D, et al. Epidemiology, Natural History, Risk Factors, and Prevention of Graves' Orbitopathy [J]. Front Endocrinol (Lausanne), 2020, 11: 615993.

[9] PERROS P, ŽARKOVIĆ M, AZZOLINI C, et al. PREGO (presentation of Graves' orbitopathy) study: changes in referral patterns to European Group on Graves' Orbitopathy (EUGOGO) centres over the period from 2000 to 2012 [J]. Br J Ophthalmol, 2015, 99(11): 1531-5.

[10] BARTALENA L, KAHALY G J, BALDESCHI L, et al. The 2021 European Group on Graves' orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves' orbitopathy [J]. Eur J Endocrinol, 2021, 185(4): G43-g67.

[11] KOTWAL A, STAN M. Current and Future Treatments for Graves' Disease and Graves' Ophthalmopathy [J]. Horm Metab Res, 2018, 50(12): 871-86.

[12] ŁACHETA D, MIŚKIEWICZ P, GŁUSZKO A, et al. Immunological Aspects of Graves' Ophthalmopathy [J]. Biomed Res Int, 2019, 2019: 7453260.

[13] PONTO K A, MERKESDAL S, HOMMEL G, et al. Public health relevance of Graves' orbitopathy [J]. J Clin Endocrinol Metab, 2013, 98(1): 145-52.

[14] KRIEGEL M A, MANSON J E, COSTENBADER K H. Does vitamin D affect risk of developing autoimmune disease?: a systematic review [J]. Semin Arthritis Rheum, 2011, 40(6): 512-31.e8.

[15] Y C. Clinical study on the level of serum vitamin D in patients with hyperthyroidism and exophthalmos [J]. Medical Equipment, 2019, 32(23): 48-9.

[16] CHENG X, JIANG T, HU A. Expression and Significance of Fibrous Growth Factor 23 and Klotho Protein in Serum of Patients with Graves Ophthalmopathy [J]. Chinese And Foreign Medical Research, 2021, 19(7): 87-9.

[17] HU Y, SUN L, XIE S, et al. Analysis of bone metabolism in patients with Graves' orbitopathy [J]. Jiangsu Med, 2016, 42(17): 1875-7.

[18] C Z. The study on correlation between serum 25-hydroxyvitamin Dconcentration and Graves disease&its complications [D]; Southwest Medical University, 2015.

[19] HEISEL C J, RIDDERING A L, ANDREWS C A, et al. Serum Vitamin D Deficiency Is an Independent Risk Factor for Thyroid Eye Disease [J]. Ophthalmic Plast Reconstr Surg, 2020, 36(1): 17-20.

[20] ZHANG H, LIANG L, XIE Z. Low Vitamin D Status is Associated with Increased Thyrotropin-Receptor Antibody Titer in Graves Disease [J]. Endocr Pract, 2015, 21(3): 258-63.

[21] PLANCK T, SHAHIDA B, MALM J, et al. Vitamin D in Graves Disease: Levels, Correlation with Laboratory and Clinical Parameters, and Genetics [J]. Eur Thyroid J, 2018, 7(1): 27-33.

[22] SMITH T J, HEGEDüS L. Graves' Disease [J]. N Engl J Med, 2016, 375(16): 1552-65.

[23] ALONSO H R, KURODA F C, PASSARINI JUNIOR J R, et al. Acupuncture and moxibustion stimulate fibroblast proliferation and neoangiogenesis during tissue repair of experimental excisional injuries in adult female Wistar rats [J]. Acupunct Med, 2020, 38(2): 93-100.

[24] FANG R, JIANG Q, GUAN Y, et al. Golgi apparatus-synthesized sulfated glycosaminoglycans mediate polymerization and activation of the cGAMP sensor STING [J]. Immunity, 2021, 54(5): 962-75.e8.

[25] ATAABADI G, DABBAGHMANESH M H, OWJI N, et al. Clinical Features of Graves' Ophthalmopathy and Impact of Enalapril on the Course of Mild Graves' Ophthalmopathy: A Pilot Study [J]. Endocr Metab Immune Disord Drug Targets, 2020, 20(1): 139-48.

[26] WOODS R S R, PILSON Q, KHARYTANIUK N, et al. Outcomes of endoscopic orbital decompression for graves' ophthalmopathy [J]. Ir J Med Sci, 2020, 189(1): 177-83.

[27] DAROSZEWSKI J, PAWLAK E, KARABON L, et al. Soluble CTLA-4 receptor an immunological marker of Graves' disease and severity of ophthalmopathy is associated with CTLA-4 Jo31 and CT60 gene polymorphisms [J]. Eur J Endocrinol, 2009, 161(5): 787-93.

[28] KHALILZADEH O, ANVARI M, ESTEGHAMATI A, et al. Genetic susceptibility to Graves' ophthalmopathy: The role of polymorphisms in anti-inflammatory cytokine genes [J]. Ophthalmic Genet, 2010, 31(4): 215-20.

[29] KIM D. The Role of Vitamin D in Thyroid Diseases [J]. Int J Mol Sci, 2017, 18(9).

[30] ATOUM M, ALZOUGHOOL F. Vitamin D and Breast Cancer: Latest Evidence and Future Steps [J]. Breast Cancer (Auckl), 2017, 11: 1178223417749816.

[31] MCCULLOUGH M L, ZOLTICK E S, WEINSTEIN S J, et al. Circulating Vitamin D and Colorectal Cancer Risk: An International Pooling Project of 17 Cohorts [J]. J Natl Cancer Inst, 2019, 111(2): 158-69.

[32] LI Y F, DONG L, WEI W B. [Research progress in relationship between vitamin D and myopia and its mechanisms] [J]. Zhonghua Yan Ke Za Zhi, 2021, 57(6): 470-6.

[33] LOPES M, LAIGINHAS R, MADEIRA C, et al. Association between Serum Vitamin D and Diabetic Retinopathy in Portuguese Patients with Type 1 Diabetes [J]. Acta Med Port, 2020, 33(7-8): 459-65.

[34] SAXENA S. Vitamin D supplementation in diabetic retinopathy in the era of COVID-19 [J]. Indian J Ophthalmol, 2021, 69(3): 483-4.

[35] BISHOP E, ISMAILOVA A, DIMELOE S K, et al. Vitamin D and immune regulation: antibacterial, antiviral, anti-inflammatory [J]. JBMR Plus, 2020, 5(1).

[36] BOTELHO I M B, MOURA NETO A, SILVA C A, et al. Vitamin D in Hashimoto's thyroiditis and its relationship with thyroid function and inflammatory status [J]. Endocr J, 2018, 65(10): 1029-37.

[37] HARRISON S R, LI D, JEFFERY L E, et al. Vitamin D, Autoimmune Disease and Rheumatoid Arthritis [J]. Calcif Tissue Int, 2020, 106(1): 58-75.